Delcath Systems, Inc. (OTCQB-DCTH) Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. MORE
- [2019-10-22] Delcath Systems Announces Postponement of Reverse Stock Split
- [2019-10-18] Delcath Systems Announces Ratio for Reverse Stock Split
- [2019-10-08] Delcath Systems to Present at the MicroCap Rodeo Investor Conference
- [2019-09-23] Delcath Systems to Participate in Upcoming Investor Conferences
- [2019-08-28] Delcath Systems Announces Presentation at the Rodman & Renshaw 21st Annual Global Investment Conference sponsored by H.C. Wainwright
You are about to review presentations, reports, filings and/or other materials regarding Delcath Systems, Inc. (NASDAQ: DCTH) that contain time-sensitive information. The information contained therein is only current as of the date thereof. Delcath expressly disclaims any obligation to review, update or correct these materials after the date thereof. Delcath may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice. Certain statements made on this Web site or in materials accessed in or through this section of our Web site are “forward–looking statements,” which are subject to risks and uncertainties, and Delcath’s actual results may differ (possibly materially) from those indicated in such statements. Data Provided by Thomson Reuters.